Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia

J Matern Fetal Neonatal Med. 2013 May;26(8):733-7. doi: 10.3109/14767058.2012.755167. Epub 2013 Jan 10.

Abstract

Objective: To investigate the potential value of maternal serum concentration of activin-A at 30-33 weeks' gestation in the prediction of preeclampsia (PE) developing at or after 34 weeks.

Methods: Serum concentrations of activin-A were measured at 11-13 and at 30-33 weeks' gestation in a case-control study of 50 cases that developed PE and 250 unaffected controls. The measured values of activin-A were converted into multiples of the unaffected median (MoM), after adjustment for maternal characteristics, and the MoM values in the PE and controls were compared.

Results: The median activin-A MoM at 30-33 weeks was higher in the PE group (1.47, IQR 1.14-2.38 versus 0.99, IQR 0.72-1.42), but at 11-13 weeks there was no significant difference between the groups. In screening by a combination of maternal characteristics and activin-A at 30-33 weeks the detection rate of PE was 50.0%, at a false positive rate of 10%.

Conclusion: Screening by maternal characteristics and activin-A at 30-33 weeks could identify half of the pregnancies that will subsequently develop PE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activins / blood*
  • Biomarkers / blood
  • Case-Control Studies
  • Female
  • Humans
  • Pre-Eclampsia / blood*
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Trimester, Third
  • Prospective Studies
  • Regression Analysis

Substances

  • Biomarkers
  • activin A
  • Activins